Printer Friendly
The Free Library
23,375,127 articles and books


Sirtex Announces New Medical Director for U.S. Operations.

LAKE FOREST, Ill. -- Sirtex, a leading developer of targeted and innovative cancer therapies, is pleased to name Dr. David Cade as its first medical director for U.S. Operations. Dr. Cade previously served as European Medical Director for Sirtex in Bonn, Germany. Sirtex manufactures SIR-Spheres(R) microspheres, the only FDA-approved radioactive microspheres for treatment of metastatic liver tumors. The company's U.S. headquarters are in Lake Forest, Ill.

Dr. Cade joined Sirtex in 2003 after serving as a global associate at Booz Allen Hamilton in Melbourne, Australia. Previously, he held a cardiothoracic surgery teaching position at the Monash Medical Centre in Melbourne, Australia. Dr. Cade received his Bachelor of Medicine Bachelor of Surgery degree from Monash University and a Masters degree in Business Administration from the Melbourne Business School in Melbourne, Australia.

"We are very excited to have Dr. Cade join our U.S. operations," says Charles Rowland, president of Sirtex Medical. "Our mission in 2006 is to advance our training and education programs to better serve physicians who administer SIR-Spheres microspheres. Dr. Cade will also play an integral role in the development of our clinical research strategy."

Sirtex's SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of SIR-Spheres microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors, sparing healthy liver tissue. Clinical research shows that the use of SIR-Spheres microspheres increases patient survival rates by an average of five to six months.

Approximately 55 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 60 medical centers. The minimally invasive procedure is performed on an out-patient basis with minor side effects.

About Sirtex

SIR-Spheres microspheres were developed in the 1980s in Australia and gained FDA approval in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, visit www.sirtex.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 22, 2006
Words:340
Previous Article:Fitch Affirms Thermo Electron's Ratings.
Next Article:Littelfuse to Acquire Concord Semiconductor.
Topics:



Related Articles
GOVERNMENT.
Government. (Brass Tracks).
Government. (Brass Tracks).
Christian Jensen.
Department of Defense news release (April 5, 2005): general officer announcements.
Survey reveals emphasis on tying pay to quality: physician executive pay increase holds steady near 7 percent.
Department of defense news release (Oct. 7, 2005): general officer assignments.
2006 U.S. Army Acquisition Corps annual Awards Ceremony.
Glenn W. Mitchell.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters